Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders

Abstract Over the last few years, fluoxetine has been one of the most prescribed medications for the treatment of diverse psychiatric conditions in Mexico. Fluoxetine therapeutic effect is consequence of the joint action of the parent drug and its active metabolite, norfluoxetine. However, the clini...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julia Sagahón‐Azúa, Susanna Edith Medellín‐Garibay, Cinthya Eloisa Chávez‐Castillo, César Guillermo González‐Salinas, Rosa del Carmen Milán‐Segovia, Silvia Romano‐Moreno
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	fluoxetine genetic factors norfluoxetine pharmacokinetics plasma concentrations Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e77275f1ed984863b55fb46fab47625a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e77275f1ed984863b55fb46fab47625a
record_format	dspace
spelling	oai:doaj.org-article:e77275f1ed984863b55fb46fab47625a2021-11-16T13:45:55ZFactors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders2052-170710.1002/prp2.864https://doaj.org/article/e77275f1ed984863b55fb46fab47625a2021-10-01T00:00:00Zhttps://doi.org/10.1002/prp2.864https://doaj.org/toc/2052-1707Abstract Over the last few years, fluoxetine has been one of the most prescribed medications for the treatment of diverse psychiatric conditions in Mexico. Fluoxetine therapeutic effect is consequence of the joint action of the parent drug and its active metabolite, norfluoxetine. However, the clinical efficacy of fluoxetine, can be affected due to diverse factors, such as drug‐drug interactions and the large interindividual variability in the pharmacokinetics of this drug. The aim of this study was to determine the factors associated with variability in plasma concentrations of fluoxetine and norfluoxetine and its association with the therapeutic response. Fluoxetine and norfluoxetine plasma concentrations were quantified by liquid chromatography in 81 Mexican patients with mental disorders; 25% of the patients had no medication adherence and 40% were below the reference range of fluoxetine plus norfluoxetine plasma concentrations. The results showed that concentrations can be affected by fluoxetine metabolism caused by CYP2D6 phenotype and the concomitant administration of olanzapine. Furthermore, CYP3A5 and CYP2C19 phenotype were associated with lower anxiety and depression control during treatment with fluoxetine. This study can be a starting point to elucidate the causes of fluoxetine variable response in Mexican patients with mental disorders, as well as to detect and support medication adherence.Julia Sagahón‐AzúaSusanna Edith Medellín‐GaribayCinthya Eloisa Chávez‐CastilloCésar Guillermo González‐SalinasRosa del Carmen Milán‐SegoviaSilvia Romano‐MorenoWileyarticlefluoxetinegenetic factorsnorfluoxetinepharmacokineticsplasma concentrationsTherapeutics. PharmacologyRM1-950ENPharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	fluoxetine genetic factors norfluoxetine pharmacokinetics plasma concentrations Therapeutics. Pharmacology RM1-950
spellingShingle	fluoxetine genetic factors norfluoxetine pharmacokinetics plasma concentrations Therapeutics. Pharmacology RM1-950 Julia Sagahón‐Azúa Susanna Edith Medellín‐Garibay Cinthya Eloisa Chávez‐Castillo César Guillermo González‐Salinas Rosa del Carmen Milán‐Segovia Silvia Romano‐Moreno Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders
description	Abstract Over the last few years, fluoxetine has been one of the most prescribed medications for the treatment of diverse psychiatric conditions in Mexico. Fluoxetine therapeutic effect is consequence of the joint action of the parent drug and its active metabolite, norfluoxetine. However, the clinical efficacy of fluoxetine, can be affected due to diverse factors, such as drug‐drug interactions and the large interindividual variability in the pharmacokinetics of this drug. The aim of this study was to determine the factors associated with variability in plasma concentrations of fluoxetine and norfluoxetine and its association with the therapeutic response. Fluoxetine and norfluoxetine plasma concentrations were quantified by liquid chromatography in 81 Mexican patients with mental disorders; 25% of the patients had no medication adherence and 40% were below the reference range of fluoxetine plus norfluoxetine plasma concentrations. The results showed that concentrations can be affected by fluoxetine metabolism caused by CYP2D6 phenotype and the concomitant administration of olanzapine. Furthermore, CYP3A5 and CYP2C19 phenotype were associated with lower anxiety and depression control during treatment with fluoxetine. This study can be a starting point to elucidate the causes of fluoxetine variable response in Mexican patients with mental disorders, as well as to detect and support medication adherence.
format	article
author	Julia Sagahón‐Azúa Susanna Edith Medellín‐Garibay Cinthya Eloisa Chávez‐Castillo César Guillermo González‐Salinas Rosa del Carmen Milán‐Segovia Silvia Romano‐Moreno
author_facet	Julia Sagahón‐Azúa Susanna Edith Medellín‐Garibay Cinthya Eloisa Chávez‐Castillo César Guillermo González‐Salinas Rosa del Carmen Milán‐Segovia Silvia Romano‐Moreno
author_sort	Julia Sagahón‐Azúa
title	Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders
title_short	Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders
title_full	Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders
title_fullStr	Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders
title_full_unstemmed	Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders
title_sort	factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in mexican patients with mental disorders
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/e77275f1ed984863b55fb46fab47625a
work_keys_str_mv	AT juliasagahonazua factorsassociatedwithfluoxetineandnorfluoxetineplasmaconcentrationsandclinicalresponseinmexicanpatientswithmentaldisorders AT susannaedithmedellingaribay factorsassociatedwithfluoxetineandnorfluoxetineplasmaconcentrationsandclinicalresponseinmexicanpatientswithmentaldisorders AT cinthyaeloisachavezcastillo factorsassociatedwithfluoxetineandnorfluoxetineplasmaconcentrationsandclinicalresponseinmexicanpatientswithmentaldisorders AT cesarguillermogonzalezsalinas factorsassociatedwithfluoxetineandnorfluoxetineplasmaconcentrationsandclinicalresponseinmexicanpatientswithmentaldisorders AT rosadelcarmenmilansegovia factorsassociatedwithfluoxetineandnorfluoxetineplasmaconcentrationsandclinicalresponseinmexicanpatientswithmentaldisorders AT silviaromanomoreno factorsassociatedwithfluoxetineandnorfluoxetineplasmaconcentrationsandclinicalresponseinmexicanpatientswithmentaldisorders
_version_	1718426515085983744

Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders

Ejemplares similares